section name header

Indications

High Alert

Unlabeled Use:

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: arrhythmias, bradycardia, hypotension.

Derm: facial itching.

EENT: blurred/double vision.

Endo: adrenal insufficiency.

GI: biliary spasm, nausea, vomiting.

MS: skeletal and thoracic muscle rigidity (with rapid IV infusion).

Neuro: confusion, paradoxical excitation/delirium, postoperative drowsiness.

Resp: allergic bronchospasm, APNEA, LARYNGOSPASM, RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA).

Interactions

Drug-Drug:

Drug-Food:

Availability

(Generic available)

Route/Dosage

see Calculator

Preoperative Use

Adjunct to General Anesthesia

Adjunct to Regional Anesthesia

Postoperative Use (Recovery Room)

General Anesthesia

Sedation/Analgesia

US Brand Names

Sublimaze

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: opioid analgesics

Pharmacologic Classification: opioid agonists

Pharmacokinetics

Absorption: Well absorbed after IM administration. IV administration results in complete bioavailability.

Distribution: Extensively distributed to CNS and tissues.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4 isoenzyme; 10–25% excreted unchanged by the kidneys.

Half-life: Children: Bolus dose — 2.4 hr, long-term continuous infusion — 11–36 hr; Adults: 2–4 hr ( after cardiopulmonary bypass and in geriatric patients).

Contr. Subst. Schedule

Schedule II (C-II)

Time/Action Profile

(analgesia*)

ROUTEONSETPEAKDURATION
IM7–15 min20–30 min1–2 hr
IV1–2 min3–5 min0.5–1 hr

*Respiratory depression may last longer than analgesia.

Patient/Family Teaching

Pronunciation

FEN-ta-nil

Code

NDC Code*